Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay

被引：0

作者：

Vidula, Neelima

Damodaran, Senthil

Bhave, Manali A.

Blouch, Erica

Ogbenna, Ogadinma

Flaum, Lisa E.

Shah, Ami N.

Abramson, Vandana G.

Cristofanilli, Massimo

Sparano, Joseph A.

Ostrer, Harry

Horick, Nora K.

Rugo, Hope S.

Bardia, Aditya

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Emory Univ, Sch Med, Atlanta, GA USA

[4] Massachusetts Gen Hosp, Boston, MA USA

[5] Northwestern Med Grp, Chicago, IL USA

[6] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[7] Vanderbilt Univ, Nashville, TN USA

[8] Weill Cornell Med, New York, NY USA

[9] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[10] Albert Einstein Coll Med, Bronx, NY USA

[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[12] UCLA, Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1143

引用

页数：1

共 50 条

[21] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
Anders, Carey K.
Le Rhun, Emilie
Bachelot, Thomas Denis
Yardley, Denise A.
Awada, Ahmad
Conte, Pier Franco
Kabos, Peter
Bear, Melissa
Yang, Zhengyu
Chen, Yanyun
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[22] Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC)
Tolaney, S. M.
Cortes, J.
Dickler, M. N.
Zamora, E.
Caldwell, C. W.
Nguyen, T. S.
Nanda, S.
Koustenis, A.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2016, 27
[23] A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)
Lynce, Filipa
Graham, Noah
Kochupurakkal, Bose S.
Huy Nguyen
Poorvu, Philip D.
Attaya, Victoria
Davis, Raechel
Garg, Kavita
Lim, Lee P.
Li, Mark
Paweletz, Cloud P.
Tayob, Nabihah
Shapiro, Geoffrey I.
Tolaney, Sara M.
CANCER RESEARCH, 2023, 83 (08)
[24] A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.
Isakoff, S. J.
Overmoyer, B.
Tung, N. M.
Gelman, R. S.
Habin, K.
Qian, J.
Giranda, V.
Shepherd, S.
Garber, J. E.
Ellisen, L. W.
Winer, E. P.
Goss, P. E.
CANCER RESEARCH, 2011, 71
[25] Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
Litton, Jennifer Keating
Beck, Joseph Thaddeus
Jones, Jason M.
Andersen, Jay
Blum, Joanne Lorraine
Mina, Lida A.
Brig, Raymond
Danso, Michael A.
Yuan, Yuan
Abbattista, Antonello
Noonan, Kay
Chakrabarti, Jayeta
Czibere, Akos
Symmans, William Fraser
Telli, Melinda L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Gruber, Joshua James
Afghahi, Anosheh
Hatton, Alyssa
Scott, Danika
McMillan, Alex
Ford, James M.
Telli, Melinda L.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Phase IV multicenter study evaluating RWE and the safety of talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a BRCA1/2 mutation (ViTAL) - Cohort 2: patients treated according to the EMA
Loirat, Delphine
de la Barre, Marie Duboys
Villanueva, Cristian
Mailliez, Audrey
Isambert, Nicolas
Moreau, Lionel
Jacquet, Emmanuelle
Spaeth, Dominique
Creisson, Anne
Jouannaud, Christelle
Legouffe, Eric
Delbado, Miguel
Deiana, Laura
Soibinet, Pauline
Hrab, Ioana
Grellety, Thomas
Dohollou, Nadine
Longo, Raffaele
Thery, Jean-Christophe
Fumet, Jean-david
Zineb, Sellam
Pujol, Pascal
de la Motte Rouge, thibault
CANCER RESEARCH, 2023, 83 (05)
[28] Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting
McFarland, Taylor Ryan
Thomas, Vinay Mathew
Nussenzveig, Roberto
Gebrael, Georges
Sayegh, Nicolas
Tripathi, Nishita
Sahu, Kamal Kant
Goel, Divyam
Maughan, Benjamin L.
Sirohi, Deepika
Agarwal, Neeraj
Swami, Umang
BIOMEDICINES, 2022, 10 (12)
[29] Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Weigelt, Britta
Comino-Mendez, Inaki
de Bruijn, Ino
Tian, Lei
Meisel, Jane L.
Garcia-Murillas, Isaac
Fribbens, Charlotte
Cutts, Ros
Martelotto, Luciano G.
Ng, Charlotte K. Y.
Lim, Raymond S.
Selenica, Pier
Piscuoglio, Salvatore
Aghajanian, Carol
Norton, Larry
Murali, Rajmohan
Hyman, David M.
Borsu, Laetitia
Arcila, Maria E.
Konner, Jason
Reis-Filho, Jorge S.
Greenberg, Roger A.
Robson, Mark E.
Turner, Nicholas C.
CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6708 - 6720
[30] Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
Litton, Jennifer K.
Laird, A. Douglas
Rugo, Hope S.
Ettl, Johannes
Hurvitz, Sara A.
Martin, Miguel
Roche, Henri
Im, Young-Hyuck
Goodwin, Annabel
Blum, Joanne L.
Eiermann, Wolfgang
Chen, Ying
Lanzalone, Silvana
Chelliserry, Jijumon
Czibere, Akos
Albacker, Lee A.
Frampton, Garrett M.
Mina, Lida A.
CANCER RESEARCH, 2020, 80 (16)

← 1 2 3 4 5 →